Dazukibart (previously known as PF-06823859) is a humanized monoclonal antibody developed by Pfizer for the treatment of autoimmune diseases, particularly dermatomyositis and systemic lupus erythematosus. It is classified as a potent, selective, humanized IgG1 neutralizing monoclonal antibody that specifically targets interferon beta (IFN-β).
Dazukibart (previously known as PF-06823859) is a humanized monoclonal antibody developed by Pfizer for the treatment of autoimmune diseases, particularly dermatomyositis and systemic lupus erythematosus. It is classified as a potent, selective, humanized IgG1 neutralizing monoclonal antibody that specifically targets interferon beta (IFN-β).
Source: Wikipedia "Dazukibart" · CC BY-SA 4.0
Share this article: X · Bluesky